Modulating sphingosine 1-phosphate receptor subtype 1 decreased bone pain and neuroinflammation in an animal model of metastasized breast cancer in the femur, according to a study in the journal Pain. "Pain is a huge problem -- for the patient, the caregiver, the family, the doctors. We have limited options," said researcher Daniela Salvemini of Saint Louis University.
Patients with a neuromodulation device implant to reduce lower-back and leg pain may prefer leads that interact over those that act independently, according to research presented at the International Neuromodulation Society's World Congress. A second study presented at the conference found high-frequency spinal cord stimulation may help treat peripheral polyneuropathy.
A study presented at a sleep conference found using morning bright-light treatment as an adjunctive treatment for fibromyalgia may help reduce pain sensitivity and improve function. Researchers found improvement gained from morning bright-light therapy was similar to that from cognitive-behavioral therapy and about half of what is gained from intense exercise therapy.
FDA Commissioner Scott Gottlieb said the agency will take "more forceful steps" to stem opioid addiction, including creating a steering committee to look at additional regulatory and policy responses. The public will be able to participate in online forums and a two-day meeting set for July 10 and 11.
The FDA has asked Endo International to withdraw its long-lasting opioid painkiller, Opana ER, from the market as the agency escalates its efforts to fight the worsening opioid abuse crisis in the country. The decision, based on indicators that a version reformulated for abuse deterrence is simply being injected rather than abused via nasal administration, marks the first time that the FDA has taken such steps to address a public health crisis.